Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Management of rheumatoid arthritis .by Dr.Harmanjit Singh,GMC, Patiala


Published on

Published in: Health & Medicine

Management of rheumatoid arthritis .by Dr.Harmanjit Singh,GMC, Patiala

  1. 1. MANAGEMENT OF RHEUMATOID ARTHRITIS Dr.Harmanjit Singh Department of Pharmacology Govt Medical College,Patiala.
  2. 2. INTRODUCTION <ul><li>RA is chronic multisystem disease of unknown cause. </li></ul><ul><li>Characteristic feature is persistent inflammatory synovitis. </li></ul><ul><li>Usually involve peripheral joints in symmetric distribution. </li></ul><ul><li>Joint changes probably represent autoimmune reaction. </li></ul>
  3. 3. <ul><li>Etiology: </li></ul><ul><li>Cause is unknown . </li></ul><ul><li>Family studies indicate genetic predisposition. </li></ul><ul><li>HLA DR4, Dw16, DR10, DR9, DR3 associated with rheumatoid arthritis. </li></ul><ul><li>HLADR5, DR7, DR2 may protect against rheumatoid arthritis ( Frequency less). </li></ul><ul><li>. May be manifestation of response to infection by mycoplasma, EBV, CMV, Parvovirus & rubella virus. </li></ul><ul><li>.Cigarette smoking – triggering factor. </li></ul>
  4. 4. <ul><li>Pathology : </li></ul><ul><li>Hyperplasia & hypertrophy of synovial cells. </li></ul><ul><li>Infiltration with mononuclear cells, macrophages. </li></ul><ul><li>Production of IL-1, IL-6 TNF alpha, PGE2, Leukotriene B4. </li></ul><ul><li>TNF alpha : proliferation of inflammatory cells </li></ul><ul><li>IL-1 : cartilage proteoglycan resorption, bone erosion,destructive aspect of RA </li></ul><ul><li>IL-6 : mediates IL-1 & TNF alpha actions </li></ul><ul><li>stimulates B cells </li></ul>
  5. 6. Diagnosis of rheumatoid arthritis Morning stiffness  1h Three or more joints involved Arthritis of hand joints Symmetric arthritis Rheumatoid nodules ( over bony prominence , extensor surfaces) Rheumatoid factor (positive < 5% normal subjects) Radiographic changes (must show erosion/decalcification) Present for  6wk Any 4 of the following must be present to allow diagnosis of RA ( Patients with 2 or more clinical diagnoses are not excluded )
  6. 7. RA- joint involvement <ul><li>Extraarticular manifestations </li></ul><ul><li>Pericarditis </li></ul><ul><li>Interstitial lung disease </li></ul><ul><li>Felty’s syndrome </li></ul><ul><li>Vasculitis </li></ul><ul><li>Neuropathy </li></ul>
  7. 8. <ul><li>INVESTIGATIONS </li></ul><ul><li>Rheumatoid Factor .   : +ve In about 80% of cases </li></ul><ul><li>- Also present in about 5% of normal individuals </li></ul><ul><li>- when it appears in patients with arthritic pain on both sides of the body, it is a strong indicator of RA. </li></ul><ul><li>ESR.   The higher the ESR the greater the inflammation., help determine how active the condition is. </li></ul><ul><li>C-Reactive Protein .  High levels of C-reactive protein (CRP) are also indicators of active inflammation.. </li></ul><ul><li>Anti-CCP Antibody Test .  The presence of antibodies to cyclic citrullinated peptides (CCP) can identify RA years before symptoms develop. </li></ul><ul><li>Tests for Anemia .   normocytic normochromic </li></ul>
  8. 9. <ul><li>IMAGING TECHNIQES </li></ul><ul><li>X-Rays, Dexa Scans . Ultrasound.  Special ultrasound techniques called power Doppler ultrasonography (PDUS) or quantitative ultrasound (QUS) may be helpful in RA. </li></ul><ul><li>Magnetic Resonance Imaging .  Specially designed magnetic resonance imaging (MRI) equipment called extremity MRI may be able detect bone erosions in the hands of RA patients where x-rays cannot. </li></ul><ul><li>Above lab findings plus clinical features are important to make the diagnosis </li></ul>
  9. 10. <ul><li>Monitoring progression </li></ul><ul><li>  Disease Activity Score of 28 joints  (DAS28). It is widely used as an indicator of RA disease activity and response to treatment The joints included in DAS28 are PIP , MCP joints, wrists ,  elbows  ,  shoulders  and  knees   </li></ul><ul><li>When looking at these joints, both the number of joints with tenderness upon touching ( TEN28 ) and swelling ( SW28 ) are counted. </li></ul><ul><li>In addition, the   ESR is measured. </li></ul><ul><li>Score less than 3.2 means pt is inactive </li></ul><ul><li>3.2-5.1 means moderately active patient </li></ul><ul><li>more than 5.1 means pt is active </li></ul>
  10. 11. Goals of therapy Alleviate pain Preservation of function Control disease activity Maximize quality of life Slow progression/rate of joint damage
  11. 12. MANAGEMENT <ul><li>Physical Therapies </li></ul><ul><li>Diet </li></ul><ul><li>Pharmacologic Therapies </li></ul><ul><li>NSAIDS </li></ul><ul><li>Glucocorticoids </li></ul><ul><li>DMARDS </li></ul><ul><li>Biologics </li></ul><ul><li>Surgical treatment </li></ul><ul><li>Future trends </li></ul>
  12. 13. MANAGEMENT <ul><li>Physical therapies </li></ul><ul><li>Splinting: prevents unwanted joint movement </li></ul><ul><li>Exercise: directed to maintain muscle strength & joint mobility </li></ul><ul><li>Diet   </li></ul><ul><li>.Some studies suggest that omega-3 fatty acids may reduce rheumatoid arthritis inflammation. </li></ul><ul><li>Some Herbal remedies also found to be useful </li></ul>
  13. 14. <ul><li>Pharmacologic measures: </li></ul><ul><li>NSAIDS </li></ul><ul><li>First line drugs in mild/early cases </li></ul><ul><li>Afford symptomatic relief in pain , swelling , morning stiffness </li></ul><ul><li>Do not arrest disease process </li></ul><ul><li>Non selective Cox inhibitors : </li></ul><ul><li>Naproxen - 500 mg bd. </li></ul><ul><li>Piroxicam -20 mg qid </li></ul><ul><li>Nabumetone 1000mg od </li></ul><ul><li>Aceclofenac , Etodolac upto 1000 mg/day </li></ul><ul><li>Indomethacin reserve dg when other NSAIDs don’t provide relief </li></ul><ul><li>Aspirin is rarely used now </li></ul><ul><li>Adverse effects :G I bleeding, ulcers, hepatoxicity, rash. </li></ul>
  14. 15. <ul><li>Selective cox-2 inhibitors : </li></ul><ul><li>Celecoxib100-200mg bd </li></ul><ul><li>Etoricoxib 90 mg od has highest selectivity ratio for inhibition of cox 2. & has superior efficacy compared with 500 mg naproxen bd over 12 weeks </li></ul><ul><li>Rafecoxib valdecoxib are obsolete now because of their cardiotoxicity </li></ul>
  15. 16. NSAID Therapy <ul><li>Disadvantages </li></ul><ul><li>Does not affect disease progression </li></ul><ul><li>GI toxicity common </li></ul><ul><li>Renal complications (eg, irreversible renal insufficiency, papillary necrosis) </li></ul><ul><li>Hepatic dysfunction </li></ul><ul><li> </li></ul><ul><li>Advantages </li></ul><ul><li>Effective control of inflammation and pain </li></ul><ul><li>Effective reduction in swelling </li></ul><ul><li>Improves mobility, flexibility, range of motion </li></ul><ul><li>Improve quality of life </li></ul><ul><li>Relatively low-cost </li></ul>
  16. 17. GLUCOCORTICOIDS <ul><li>Second line agents </li></ul><ul><li>Mostly combined with NSAIDS </li></ul><ul><li>Pharmacological actions </li></ul><ul><ul><li>Antiinflammatory & immunosuppressant action </li></ul></ul><ul><ul><li>Suppress signs & symptoms </li></ul></ul><ul><ul><li>Slow appearance of new bone erosions </li></ul></ul>
  17. 18. GLUCOCORTICOIDS <ul><li>PKs </li></ul><ul><li>Route: </li></ul><ul><ul><li>Oral </li></ul></ul><ul><ul><li>Intraarticular- transient symptomatic therapy when systemic therapy fails, don’t repeat before 4-6 months </li></ul></ul><ul><li>Dose </li></ul><ul><ul><li>Prednisolone- 7.5 mg/d, or equivalent </li></ul></ul><ul><ul><li>Reduce dose gradually </li></ul></ul>
  18. 19. GLUCOCORTICOIDS: ADRs <ul><li>Cushing’s habitus </li></ul><ul><li>Infections </li></ul><ul><li>Delayed healing </li></ul><ul><li>Peptic ulcers </li></ul><ul><li>Cataract </li></ul><ul><li>Glaucoma </li></ul><ul><li>Growth retardation </li></ul><ul><li>Muscle weakness </li></ul><ul><li>Mood changes </li></ul><ul><li>Osteoporosis </li></ul><ul><li>Hyperglycemia </li></ul>
  19. 20. Corticosteroid Therapy <ul><li>Disadvantages </li></ul><ul><li>Does not conclusively affect disease progression </li></ul><ul><li>Tapering and discontinuation of use often unsuccessful </li></ul><ul><li>Low doses result in skin thinning, ecchymoses, and Cushingoid appearance </li></ul><ul><li>Significant cause of steroid-induced osteopenia </li></ul><ul><li>Advantages </li></ul><ul><li>Anti-inflammatory and immunosuppressive effects </li></ul><ul><li>Can be used to bridge gap between initiation of DMARD therapy and onset of action. </li></ul><ul><li>Intra-articular injections can be used for individual joint flares </li></ul>
  20. 21. <ul><li>Disease modifying anti rheumatic dgs (DMARDs): </li></ul><ul><li>- Current recommendation is to add DMARDs as soon as the diagnosis is confirmed </li></ul><ul><li>-Slow acting, take 6wks to 6 months to show the effects. </li></ul><ul><li>-They modify/ alter disease progression </li></ul><ul><li>Commonly used DMARDs are -: </li></ul><ul><li>- Mehotrexate </li></ul><ul><li>- Sulphasalazine </li></ul><ul><li>- Chloroquine & Hydroxychloroquine </li></ul><ul><li>- Leflunomide </li></ul><ul><li>- cyclosporine </li></ul><ul><li>- Azathioprine </li></ul>
  21. 22. Advantages of DMARDs <ul><li>Slow disease progression </li></ul><ul><li>Improve functional disability </li></ul><ul><li>Decrease pain </li></ul><ul><li>Interfere with inflammatory processes </li></ul><ul><li>Retard development of joint erosions </li></ul>
  22. 23. Combination DMARD therapy <ul><li>MTX + SSZ </li></ul><ul><li>MTX + Hydroxychloroquine </li></ul><ul><li>MTX + cyclosporine </li></ul><ul><li>MTX + Leflunomide </li></ul><ul><li>Excellent safety & improved efficacy over MTX alone </li></ul>
  23. 24. Who should be put on combination of DMARDs? <ul><li>Failure to respond to > one DMARD / partial response </li></ul><ul><li>When to change? </li></ul><ul><li>- If response is not adequate / toxicity develops </li></ul>
  24. 25. How to combine two drugs? <ul><li>'step-up' approach : (easier to control ADR, may use only one drug in those who respond) </li></ul><ul><li>consisting of starting the patient on a first DMARD followed by the addition of a second if there is no adequate response </li></ul><ul><li>'step-down' approach : (better control in early RA) </li></ul><ul><li>in which initial combination therapy is followed by a reduction of the dose or the abandonment of one or more of the DMARDs. </li></ul>
  25. 26. <ul><li>Methotrexate: </li></ul><ul><li>Considered first choice to treat RA </li></ul><ul><li>MOA: it probably relates to inhibition of aminoimidazolecarboxamide ribonucleotide (AICAR) transformylase & thymidylate synthetase </li></ul><ul><li>It has secondary effects on PMN cells chemotaxis. </li></ul><ul><li>It has direct inhibitory effects on proliferation and stimulates apoptosis in immune - inflammatory cells </li></ul><ul><li>Orally 70% absorption </li></ul><ul><li>Dose 15-25 mg weekly, starting with 7.5 mg </li></ul>
  26. 27. <ul><li>Adverse effects of Methotrexate: </li></ul><ul><li>Nausea, mucosal ulcers. </li></ul><ul><li>Dose related hepatotoxicity. </li></ul><ul><li>Leucovorin used to reduce side effects. </li></ul><ul><li>Contraindicated in pregnancy. </li></ul>
  27. 28. <ul><li>Sulfasalazine: </li></ul><ul><li>It is metabolised to sulfapyridine & 5- aminosalicylic acid. </li></ul><ul><li>In treated arthritis patients, IgA & IgM rheumatoid factor production are decreased. </li></ul><ul><li>Suppression of T cell responses to concanavalin (glycoprotein that play role in cell cell interaction in inflammatory cell). </li></ul><ul><li>Inhibition of in vitro B cell proliferation. </li></ul><ul><li>Reduces radiologic disease progression. </li></ul>
  28. 29. <ul><li>Ad effects : N, V </li></ul><ul><li>headache </li></ul><ul><li>rash </li></ul><ul><li>Hemolytic anaemia </li></ul><ul><li>methemoglobinemia </li></ul><ul><li>Neutropenia </li></ul><ul><li>Pulmonary toxicity </li></ul><ul><li>Reversible infertility only in men. </li></ul><ul><li>Dose : 40 m g/kg/day </li></ul>
  29. 30. <ul><li>Chloroquine & Hydroxychloroquine </li></ul><ul><li>Proposed mech : </li></ul><ul><li>Suppresion of T lymphocytes response to mitogen </li></ul><ul><li>Decrease chemotaxis </li></ul><ul><li>Stablization of lysosomal enzymes </li></ul><ul><li>A/E: - N/V, abdominal pain, Rash </li></ul><ul><li>Retinitis : More with Chloroquine </li></ul><ul><li>CNS: convulsions </li></ul><ul><li>Cardiac depression </li></ul><ul><li>Dose :Chloroquine : 200 mg/day </li></ul><ul><li>Hydroxychloroquine : upto 6.4 mg/kg/day </li></ul>
  30. 31. <ul><li>Leflunomide: </li></ul><ul><li>MOA: its active metabolite ( A77-1726) inhibits dihydroorotate dehydrogenase and causes arrest of dividing T cells and inhibition of production of autoantibodies by B cells </li></ul><ul><li>in RA it is as effective as MTX </li></ul><ul><li>Inhibits bony damage </li></ul><ul><li>A/e diarrhoea, Hepatitis (FDA boxed warning), alopecia, wt gain, HTN </li></ul><ul><li>C/I : pregnancy </li></ul><ul><li>DOSE : 20mg/day </li></ul>
  31. 32. GOLD COMPOUNDS <ul><li>MOA: </li></ul><ul><li>Alters morphology & functional capabilities of macrophages </li></ul><ul><li>Inhibiting monocyte chemotactic factor-1, IL-8, 1 β & VEGF </li></ul><ul><li>Additionally </li></ul><ul><li>Alter lysosomal enzyme activity </li></ul><ul><li>Reduce histamine release from mast cells </li></ul><ul><li>Formulations- </li></ul><ul><li>Oral: auranofin (29% elemental gold) </li></ul><ul><li>I/M: aurothiomalate, aurothioglucose (50% elemental gold) </li></ul>
  32. 33. GOLD COMPOUNDS <ul><li>Dose : IM gold: Test dose of 5-25 mg & then 50 mg wkly for 20 wks </li></ul><ul><li>Oral gold: 6 mg daily in 1 or 2 doses </li></ul><ul><li>ADRs :-Pruritic skin rash, eosinophilia,Stomatitis & metallic taste,Aplastic anemia- rare, but fatal </li></ul><ul><li>Proteinuria (8-10% pts), nephrotic syndrome </li></ul><ul><li>Corneal gold deposition </li></ul><ul><li>Nitritoid rxns- sweating, flushing & headache, sp. with gold thiomalate </li></ul><ul><li>Rarely used now because of Questnable efficacy and high Toxicity </li></ul>
  33. 34. D-PENICILLAMINE <ul><li>A copper chelating agents </li></ul><ul><li>Gold like action in RA </li></ul><ul><li>Dose: Start with 125-250 mg OD, then 250 mg BD </li></ul><ul><li>ADRs : Same as gold </li></ul><ul><li>Other: loss of taste, SLE & Myasthenia gravis </li></ul><ul><li>Rarely used because of toxicity </li></ul><ul><li>OTHER drugs approved are Chlorambucil, Cyclophosphamide , Cyclosporine, Azathioprine </li></ul>
  34. 35. <ul><li>Biologic therapies, or biologics </li></ul><ul><li>Newer drugs that reduce RA inflammation in a more highly targeted manner than the DMARDs. These are used when there is inadequate response with the DMARDS </li></ul><ul><li>Biologics are made through biotechnology and target very specific proteins or cells that are involved in the inflammatory process. </li></ul><ul><li>Biologics have also been shown to help reduce the progression of joint damage in RA. </li></ul><ul><li>The currently available biologic therapies for RA must either be injected under the skin [etanercept, adalimumab, anakinra] or infused [infliximab, abatacept, and rituxumab]). </li></ul>
  35. 36. <ul><li>TNF α inhibitors </li></ul><ul><li>Etanercept: </li></ul><ul><li>MOA: it is recombinant fusion protein consisting of two soluble TNF p75 receptor moieties linked to Fc portion of human IgG1, it binds TNF α molecule </li></ul><ul><li>It decreases rate of formation of new erosion </li></ul><ul><li>DOSE: 25 mg twice weekly given s.c. </li></ul><ul><li>A/E </li></ul><ul><li>- Opportunistic infections, Activation of latent TB </li></ul>
  36. 37. <ul><li>Adalimumab </li></ul><ul><li>MOA: it is fully human IgG1 anti TNF monoclonal antibody complexes with soluble TNF α and prevents its interaction with cell surface receptors causing down regulation of macrophages and Tcell function </li></ul><ul><li>DOSE: 40 mg given every 2 weely given s.c. </li></ul><ul><li>Respiratory infection is a common a/e </li></ul><ul><li>Comb with MTX to improve response </li></ul>
  37. 38. <ul><li>Infliximab </li></ul><ul><li>MOA: it is chimeral IgG1 monoclonal antibody that binds with TNF α </li></ul><ul><li>DOSE: 3-10 mg/kg as an i.v. infusion every 8 weekly </li></ul><ul><li>Comb with MTX improves response and decreases rate of formtion of new erosions more than MTX alone </li></ul><ul><li>A/E: URTI, nausea, headache, sinusitis, rash, activation of latent TB </li></ul><ul><li>C/I: multiple sclerosis as demyelinating syndromes have been reported </li></ul>
  38. 39. TNf-  blocking agents More effective in combination with methotrexate Drug Primary action ROA Usual dose Half life Infliximab Chimeric anti TNF- Ab I/V inj. 3 mg/kg at 0,2,6 wks, then 8 wkly. Gradual ↑ to 10 mg/kg if incomplete response 9 days Etanercept Soluble TNF fusion protein, Binds TNF- α & β S/C inj. 25 mg twice/wk or 50 mg once/wk 4 days Adalimumab Human anti- TNF- α Ab S/C inj. 40 mg every 2 nd wk 2 wks
  39. 40. <ul><li>IL-1 ANTAGONIST </li></ul><ul><li>Anakinra - It is recombinant human IL-1 receptor antagonist. </li></ul><ul><li>Used in cases who have failed on others drugs. </li></ul><ul><li>A/e local reaction on s/c inj. & chest infection </li></ul><ul><li>Do not use in combination with TNF-alpha antagonists </li></ul>
  40. 41. IL-1R antagonists: ANAKINRA
  41. 42. IL-6 BLOCKING AGENT : TOCILIZUMAB <ul><li>IL-6 activation leads to systemic inflammatory manifestations and abnormal lab findings in patients with RA. </li></ul><ul><li>Tocilizumab is a Humanized anti IL-6 monoclonal Ab that specifically inhibits the action of 1L-6 </li></ul><ul><li>It is reserved for Resistant RA </li></ul>
  42. 43. <ul><li>Abatacept: </li></ul><ul><li>It is recombinant fusion protein. </li></ul><ul><li>MOA: inhibits activation of T cell </li></ul><ul><li>DOSE: depends on body wt it is given as i.v inj. </li></ul><ul><li><60 kg: 500mg </li></ul><ul><li>60-100 kg: 750 mg </li></ul><ul><li>>100kg: 1000mg. </li></ul>
  43. 44. <ul><li>Used when there is inadequate response to DMARDS </li></ul><ul><li>A/e : </li></ul><ul><li>Risk of infections </li></ul><ul><li>Hypersensitivity reaction </li></ul><ul><li>Unfortunately not all patients respond sufficiently to TNF blockade and some of the patients become unresponsive to TNF-blocking agents. </li></ul>
  44. 45. B CELL DEPLETION THERAPY <ul><li>Targeting B-lymphocytes in these patients has opened a new therapeutic window </li></ul><ul><li>Rituximab </li></ul><ul><li>Chimeric monoclonal Ab, targets CD20 B cells </li></ul><ul><li>Used in resistant RA . Benefit in treatment of RA refractory to antiTNF agents </li></ul><ul><li>Combination therapy with methotrexate </li></ul><ul><li>Dose: 2 IV infusions 2 wks apart </li></ul><ul><li>ADRs: Mild infusion reactions (infrequent) </li></ul>
  46. 47. Adverse Effects of Biologics <ul><li>Infusion related : dyspnoea , chest pain , rash, hypotension </li></ul><ul><li>Serious Infections </li></ul><ul><ul><li>TB : Activation of latent TB </li></ul></ul><ul><ul><li>Skin and soft tissue </li></ul></ul><ul><li>Malignancy ? Lymphoma,? Solid Tumors </li></ul><ul><li>OTHERS </li></ul><ul><li>Optic neuritis, demyelination , Cytopenias, Increase LFT, ILD, Vasculitis; </li></ul><ul><li>Pregnancy: stop before 3 months </li></ul><ul><li>No live vaccines should be given </li></ul>
  47. 48. SURGICAL TREATMENT <ul><li>Reserved for pts with severely damaged joints </li></ul><ul><li>Includes </li></ul><ul><li>Arthroplasty/Total joint replacement </li></ul><ul><li>Open/arthroscopic synovectomy </li></ul><ul><li>Reconstructive hand surgery </li></ul>
  48. 49. FUTURE PROSPECTIVES compound MOA Development phase USA EU TNF inhibitors CDP-870 Anti-TNF Ab fragment III III Pegsunercept Pegylated soluble TNF R type 1 II ISIS-104838 TNF-  antisense inhibitors II AGIX4207 TNF inhibitor (oral) II II IL based therapies Atlizumab Humanized anti-IL6 R monoclonal Ab II I HuMAX-IL-15/AMG-714 Anti-IL-15 monoclonal Ab II II ABT-874/J-695 Anti-IL-12 monoclonal Ab II II
  49. 50. FUTURE PROSPECTIVES Compound MOA Development phase USA EU Cell adhesion molecule inhibitors Natalizumab Humanized monoclonal Ab II II Co-stimulation inhs CTLA4-Ig CD27/B7 pathway inhibitor III Alefacept CD2 antagonist II
  50. 51. FUTURE PROSPECTIVES Immunoadsorption Apheresis – new technique used in pts who are not responding to drug therepy Compound MOA Development phase USA EU Other therapies CCI-779/ Temsirolimus Cell cycle inhibitor II Belimumab Ab against B cell stimulator protein II AT-001/dnaJp1 Heat shock derived protein II
  51. 52. <ul><li>FDA Adds Boxed Warning To Leflunomide For Severe Liver Injury </li></ul><ul><li>July 13, 2010 — The rheumatoid arthritis drug leflunomide has received a boxed warning about the risk for severe liver injury. </li></ul><ul><li>The FDA identified 49 cases of severe liver injury associated with the drug, including 14 cases of fatal liver failure. </li></ul>
  52. 54. <ul><li>Summary </li></ul><ul><li>Rheumatoid arthritis is a common autoimmune disease that can lead to serious functional limitations, joint destruction, extra-articular disease, poor quality of life, and premature death </li></ul><ul><li>Early recognition of arthritis and speedy referral to a rheumatologist are essential </li></ul><ul><li>Treatment should start early and aggressively to prevent functional limitations and structural damage </li></ul><ul><li>Innovations in treatment and monitoring have resulted in patients achieving early and sustained clinical and radiographic remission </li></ul><ul><li>Methotrexate is the first line drug, but in high risk patients early combination of methotrexate with prednisone or a tumour necrosis factor inhibitor improves outcomes </li></ul>
  53. 55. <ul><li>Thanks…… </li></ul>